Fingerprint
Dive into the research topics of 'Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically